poisar

Stocks · News reference

Gold Gains Over 1%; PepsiCo Shares Fall After Q2 Results

Avi Kapoor

U.S. stocks higher, Dow gains over 150 points. NASDAQ up 0.84%, S&P 500 up 0.60%. Tech shares jump 1.3%, communication services down 1.7%. PepsiCo falls 5% on earnings miss. VRAX up 260%, FBRX up 42%, RKTO up 36%. AFJK drops 47%, GLOO down 19%, RXT down 23%. Oil down 0.9%, gold up 1.3%, silver up 3.6%, copper up 2.6%. European markets mostly higher, Asian markets mixed. U.S. jobless claims decline to 215,000.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

AFJKFBRXGLOOPEPRKTORXTVRAX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. SEC EDGAR

    8-K filing — Forte Biosciences, Inc. (FBRX)

    Filed: 2026-08-27 AccNo: 0001140361-26-034698 Size: 302 KB Item 2.01: Completion of Acquisition or Disposition of Assets Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 3.03: Material Modifications to Rights of Security Holders Item 5.01: Changes in Control of Registrant Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits

    FBRX
  3. Na

    argenx Completes Acquisition of Forte Biosciences, Inc.

    argenx successfully completed its acquisition of Forte Biosciences for $77.00 per share in cash, adding FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease. The acquisition expands argenx's immunology portfolio and supports its Vision 2030 strategy to become a leading immunology innovation company by targeting diseases with limited treatment options.

    ARGXFBRX
  4. Na

    argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

    argenx announced a tender offer to acquire Forte Biosciences for $77 per share in cash. The acquisition adds Forte's first-in-class anti-CD122 monoclonal antibody FB102 to argenx's immunology pipeline. The tender offer commenced on August 6, 2026, with an expiration date of August 26, 2026, and is not subject to a financing condition. Forte's Board of Directors has recommended stockholders accept the offer.

    ARGXFBRX